报告题目一： Neurobiology and Pharmacotherapy of Stimulant Dependence

报告人：Thomas R. Kosten, M.D.

Professor of Psychiatry and Neuroscience at Baylor College of Medicine and former Professor and Chief of Psychiatry at Yale University and VA Connecticut, US

地      点：中国药物依赖性研究所五层会议室

时      间：2007年9月24日（周一）3:00-5:00 PM

主  持  人：陆林教授

报告题目二：Substance abuse pharmacotherapy

报告人：Thomas R. Kosten, M.D.

Professor of Psychiatry and Neuroscience at Baylor College of Medicine and former Professor and Chief of Psychiatry at Yale University and VA Connecticut, US

地      点：中国药物依赖性研究所五层会议室

时      间：2007年9月25日（周二）8:00-10:00 AM

主  持  人：陆林教授

Kosten 教授介绍：

Thomas R. Kosten, M.D. is a Professor of Psychiatry and Neuroscience at Baylor College of Medicine and former Professor and Chief of Psychiatry at Yale University and VA Connecticut. He is Research Director of the VA National Substance Use Disorders Quality Enhancement Research Initiative (QUERI) based at the Houston VA. He is founder of the Division of Substance Abuse at Baylor and Yale and directs their NIH Medications Development Center for substance abuse. He has been supported by a Research Scientist Award from the National Institute of Health since 1987 and has served on national and international review groups for medications development in substance abuse. He has been a Congressional Fellow in the House of Representatives and a visiting Professor in German, Spain, Greece, China and Canada. He is the founding Vice Chair for Added Qualifications in Addiction Psychiatry of the American Board of Psychiatry and Neurology. He is a Distinguished Fellow in the American Psychiatric Association and fellow of the American College of Neuropsychopharmacology, Past President of the American Academy of Addiction Psychiatry, and President of the College on Problems of Drug Dependence. He has several major awards for clinical research, and is the Chief Editor of two major Journals (SCI) in substance abuse and been on the American Journal of Psychiatry board. Recent work includes serving on the National Academy of Sciences, Institute of Medicine Committee on vaccines for substance abuse. From his studies in substance dependence, post traumatic stress disorder and neuroimaging, he has published over 450 papers, books and reviews. His neuroimaging research includes detecting and treating cocaine induced cerebral perfusion defects, and using functional MRI to predict pharmacotherapy outcome. His medication contributions include a cocaine vaccine, immunotherapy for hallucinogens, buprenorphine for opioid dependence, disulfiram for cocaine dependence, vasodilators for cocaine induced cerebral perfusion defects, and combining medications with contingency management for opioid and cocaine dependence.